Clear the zombie cells left behind by chemotherapy and radiotherapy
Treatment leaves behind damaged cells that stop dividing but do not die, and they release signals that help surviving cancer cells regrow. Removing them could reduce relapse.
Therapy-induced senescence produces a secretory phenotype that promotes proliferation, angiogenesis and immune suppression, and senescent tumour cells can re-enter the cell cycle. Senolytics such as navitoclax-class BCL-2 family inhibitors and dasatinib-quercetin combinations clear these cells in models, and a one-two sequence of pro-senescence therapy followed by a senolytic has shown benefit preclinically.
- Acquired resistance to every therapy · Nearly every targeted therapy stops working within months to a few years as the tumour adapts.
- Survivorship and late effects are neglected · Tens of millions of people live after cancer with heart damage, infertility, second cancers and fear, and few services.
Pages like this
not linked directly; found by shared links- PersonAnthony Letai
Shares Intrinsic apoptosis (BCL-2 family), BCL-2.
- TechnologySenolytics and senescence-directed therapy
Shares BCL-2, Cytotoxic chemotherapy.
- IdeaOne-two punch: clear senescent cells after chemotherapy
Shares Intrinsic apoptosis (BCL-2 family), BCL-2.
- TermHallmark: resisting cell death
Shares Intrinsic apoptosis (BCL-2 family), BCL-2.
- TrialVIALE-A
Shares Intrinsic apoptosis (BCL-2 family), BCL-2.
- PersonDonald Pinkel
Shares Survivorship and late effects are neglected, Cytotoxic chemotherapy.
- PathwayExtrinsic apoptosis (death receptors)
Shares Intrinsic apoptosis (BCL-2 family), BCL-2.
- IdeaBTK degraders to pre-empt resistance in frontline CLL